{
    "root": "e80b626b-701e-4b20-a6b3-77b064c8d495",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pregabalin",
    "value": "20250301",
    "ingredients": [
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        }
    ],
    "indications": "pregabalin capsules indicated : \u2022 management neuropathic pain associated diabetic peripheral neuropathy \u2022 management postherpetic neuralgia \u2022 adjunctive therapy treatment partial-onset seizures patients 1 month age older \u2022 management fibromyalgia \u2022 management neuropathic pain associated spinal cord injury",
    "contraindications": "\u2022 adult , begin dosing 150 mg/day . partial-onset seizure dosing pediatric patients 1 month age older , refer section error ! hyperlink reference valid . . ( error ! hyperlink reference valid . , error ! hyperlink reference valid . , error ! hyperlink reference valid . , error ! hyperlink reference valid . , error ! hyperlink reference valid . ) \u2022 dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial-onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14 mg/kg/day . fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . dose adjusted adult patients reduced renal function . ( error ! hyperlink reference valid . )",
    "warningsAndPrecautions": "75 mg capsules : light peach opaque cap / white opaque body size ' 4 ' hard gelatin capsules imprinted '140 ' cap ' j ' body black ink , filled white white powder . bottle 60 capsules ndc 82804-170-60 bottle 90 capsules ndc 82804-170-90 storage handling store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) [ usp controlled room temperature ] .",
    "adverseReactions": "pregabalin capsules contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( error ! hyperlink reference valid . ) ] .",
    "indications_original": "Pregabalin capsules are indicated for:\u00a0      \u2022 Management of neuropathic pain associated with diabetic peripheral neuropathy\u00a0      \u2022 Management of postherpetic neuralgia\u00a0      \u2022 Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older      \u2022 Management of fibromyalgia\u00a0      \u2022 Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "\u2022 For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section Error! Hyperlink reference not valid. . ( Error! Hyperlink reference not valid. , Error! Hyperlink reference not valid. , Error! Hyperlink reference not valid. , Error! Hyperlink reference not valid. , Error! Hyperlink reference not valid. ) \u2022 Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain (2.2) 3 divided doses per day 300 mg/day within 1 week PHN (2.3) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More (2.4) 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial-Onset Seizures in Pediatric Patients Weighing Less than 30 kg (2.4) 1 month to less than 4 years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia (2.5) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury (2.6) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Dose should be adjusted in adult patients with reduced renal function. ( Error! Hyperlink reference not valid. )",
    "warningsAndPrecautions_original": "75 mg capsules:\n                       Light peach opaque cap / white opaque body size '4' hard gelatin capsules imprinted with '140' on cap and 'J' on body with black ink, filled with white to off white powder.    \n                  \n                   Bottle of 60 capsules\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 82804-170-60\n                   Bottle of 90 capsules\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 82804-170-90        \n                       Storage and Handling\u00a0      Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pregabalin capsules are contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy     [see Warnings and Precautions (       \n                     Error! Hyperlink reference not valid.\n                     )]     ."
}